EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Integrated LC–MS/MS Approach for the Quantitative Profiling of Sofosbuvir, Voxilaprevir, and Velpatasvir in Rat Plasma: Method Validation and Preclinical Insights

Ramya Nagabathula, Kamepalli Sujana

Journal of Applied Pharmaceutical Science · 2026-07 · 16 (7) · 318-330

DOI: 10.1177/22313354261443045 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Applied Pharmaceutical Science, online erschienen am 02.05.2026. Verfasst von Ramya Nagabathula und 1 weiteren Autor:innen. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The study aimed to develop and validate a precise, reliable, and sensitive LC–MS/MS method for the simultaneous estimation of Sofosbuvir (SOF), Voxilaprevir (VOX), and Velpatasvir (VEL) in rat plasma for pharmacokinetic applications. Plasma samples were protein-precipitated and analyzed using an Agilent Eclipse XDB C18 column with an acetonitrile–ammonium formate (20:80, pH 3.0) mobile phase, and detection was carried out on a SCIEX QTRAP 5500 in MRM mode. Optimized mass transitions were m/z 530.4537 → 294.1257 for SOF, 869.9463 → 259.6483 for VOX, 884.0635 → 761.3207 for VEL, and 883.0154 → 587.4326 for the internal standard, Elbasvir. The method demonstrated excellent linearity ( R 2 > 0.999), acceptable precision (%CV ≤ 15%), and accuracy (85%–115%). Recovery of all analytes ranged from 95.39% to 98.74%, with negligible matrix effects. The LLOQ values were 20 ng/mL for SOF, 5 ng/mL for VOX, and 5 ng/mL for VEL. The developed method demonstrated acceptable accuracy, precision, and sensitivity for preclinical pharmacokinetic applications. The method was successfully applied to a rat pharmacokinetic study, indicating its suitability for exploratory bioanalytical investigations.

Zitieren

APA

Nagabathula, R., & Sujana, K. (2026). Integrated LC–MS/MS Approach for the Quantitative Profiling of Sofosbuvir, Voxilaprevir, and Velpatasvir in Rat Plasma: Method Validation and Preclinical Insights. Journal of Applied Pharmaceutical Science, 16(7), 318-330. https://doi.org/10.1177/22313354261443045

Vancouver

Nagabathula R, Sujana K. Integrated LC–MS/MS Approach for the Quantitative Profiling of Sofosbuvir, Voxilaprevir, and Velpatasvir in Rat Plasma: Method Validation and Preclinical Insights. Journal of Applied Pharmaceutical Science. 2026;16(7):318-330. doi:10.1177/22313354261443045

BibTeX
@article{Nagabathula2026,
  author = {Nagabathula, Ramya and Sujana, Kamepalli},
  title = {Integrated LC–MS/MS Approach for the Quantitative Profiling of Sofosbuvir, Voxilaprevir, and Velpatasvir in Rat Plasma: Method Validation and Preclinical Insights},
  journal = {Journal of Applied Pharmaceutical Science},
  year = {2026},
  volume = {16},
  number = {7},
  pages = {318--330},
  doi = {10.1177/22313354261443045}
}
Kostenlos starten →